Skip to main content

Appointment of Chief Medical Officer at Moberg Pharma

STOCKHOLM, August 13th, 2018, Moberg Pharma AB (OMX: MOB) announces the appointment of Shaw Sorooshian as Vice President and Chief Medical Officer of Moberg Pharma. Shaw Sorooshian will during the fall be joining the management team at Moberg Pharma coming from a previous position as Senior Director Global Medical Affairs at Sobi AB.

Moberg Pharma is pleased to announce the appointment of Shaw Sorooshian as new Vice President and Chief Medical Officer at Moberg Pharma. Shaw Sorooshian will be replacing Kjell Rensfeldt in the management team, bringing extensive experience from his previous position as Senior Director Global Medical Affairs at Sobi AB (Swedish Orphan Biovitrum) as well as preceding senior positions at Shire, Lundbeck and Organon Laboratories. Shaw Sorooshian was born in 1964 and is certified in Pharmaceutical Medicine. He has a Medical degree from the University of Edinburgh and has undergone postgraduate training in anesthesiology.

“We look forward to welcoming Shaw to Moberg Pharma. He will be joining the company in a highly exciting stage as we approach phase 3-results for MOB-015, where he will be adding valuable experience from the development, launch and commercialization of novel treatments”, says Peter Wolpert, CEO Moberg Pharma.

Kjell Rensfeldt will be retiring during the fall but will continue to serve as Senior Advisor to Moberg Pharma on a part-time basis. 

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10.30 a.m. CET on August 13th, 2018.

For additional information, please contact:
Peter Wolpert, CEO, telephone: +46 70 735 71 35, e-mail:

About Moberg Pharma,
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail®(Emtrix®, Zanmira®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).